A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
- Study ID
- NCT02460068
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Brain Metastases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fotemustine — DRUGFotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
- Fotemustine and Ipilimumab — DRUGFotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
- Ipilimumab and nivolumab — DRUGipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
Study Details
This Phase 3, open-label, triple arm study aims to evaluate the overall survival (OS) of fotemustine versus the combination of ipilimumab and fotemustine or the combination of Ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis.
Key Dates
- Start date
- Dec 31, 2012
- Status verified
- May 2015
- Primary completion
- Jan 31, 2018
- Completion
- Jan 31, 2020
Study Design
- Enrollment
- 168 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: fotemustinefotemustine alone
- Experimental: fotemustine and ipilimumabfotemustine in combination with ipilimumab
- Experimental: ipilimumab and nivolumabipilimumab in combination with nivolumab
Primary Outcome Measure
Overall Survival (OS) [ Time Frame: 2 years ]
Central Contacts
- Anna Maria Di Giacomo, PhD,MD0577-586305
- Michele Maio, PhD,MD0577-586335
Related Studies
- Stereotactic Radiosurgery Dose Escalation for Brain MetastasesPHASE1 · Recruiting · University of Utah · Salt Lake City, Utah
- Frameless Stereotactic Radiosurgery for Intact Brain MetastasesPHASE2 · Recruiting · University of Chicago · Chicago, Illinois
- Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain MetastasesRecruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Washington D.C., District of Columbia
- Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsPHASE1/PHASE2 · Recruiting · Weill Medical College of Cornell University · New York, New York